Sandoz’s Pierre Bourdage talks to us about biosimilars and how uptake can be boosted.

How a holistic approach to horseshoe crab sustainability will allow the industry to maintain stocks while protecting patients.

Can AI facilitate a grand comeback for medicines sourced from Mother Nature?

Clinical supply chains are inherently dynamic and ambiguous, contributing to a high degree of uncertainty.

We interview Mary Lavin, President of Sartorius North America, about her career.

Lonza and Cytena combine expertise to allow biotherapeutic manufacturers to benefit from the advantages of Pichia pastoris as an expression system.

Epigenetic switches are being used to identify the optimal combination of transcription factors required to derive clinically valuable cell types.

How a new 3D bioprinter could – quite literally – add a new dimension to drug screening and disease modeling.

Andes-based cannabis cultivator Clever Leaves pledges to send US$25 million of leaves to US researchers.

A husband-and-wife-led team used mass spec to identify new drugs that “glue” proteins together. We spoke to Aneika Leney about the project.